Advanced search
Publication Cover
Current Medical Research and Opinion Volume 26, 2010 - Issue 2
Submit an article Journal homepage
218
Views
22
CrossRef citations to date
0
Altmetric
Original Article

Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study

Mauricette Michallet Hospices Civils de Lyon, Lyon, FranceCorrespondence[email protected]
,
Michel Tulliez Hôpital Henri Mondor, Créteil, France
,
Sélim Corm Hôpital Claude Huriez, Lille, France
,
Martine Gardembas Centre Hospitalier Universitaire, Angers, France
,
Françoise Huguet CHU Purpan, Toulouse, France
,
Abderrahim Oukessou Bristol-Myers Squibb, Rueil-Malmaison, France
,
Bruno Bregman Bristol-Myers Squibb, Rueil-Malmaison, France
,
Anne Vekhoff Hôpital Hôtel Dieu, Paris, France
,
Kamel Ghomari Centre Hospitalier de Beauvais, Beauvais, France
,
Nathalie Cambier Hôpital Saint Vincent, Lille, France
&
Agnès Guerci-Bresler CHU Brabois, Vandoeuvre les Nancy, France
 show all
Pages 307-317 | Accepted 11 Nov 2009, Published online: 04 Dec 2009

Citations (22)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Rubin Cheng, Yilan Huang, Yun Fang, Qirui Wang, Meixiu Yan & Yuqing Ge. (2021) Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia. Pharmaceutical Biology 59:1, pages 891-901.
Read now
Patricia Kropf, Gisoo Barnes, Boxiong Tang, Ashutosh Pathak & Jean-Pierre J. Issa. (2016) Healthcare utilization and costs associated with tyrosine kinase inhibitor switching in patients with chronic myeloid leukemia. Leukemia & Lymphoma 57:4, pages 935-941.
Read now
Elias J Jabbour, Jorge E Cortes & Hagop M Kantarjian. (2013) Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia. Expert Review of Anticancer Therapy 13:12, pages 1433-1452.
Read now
Lei Chen, Annie Guérin, Jipan Xie, Eric Q. Wu, Andrew P Yu, Solveig G. Ericson & Elias Jabbour. (2012) Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis. Current Medical Research and Opinion 28:11, pages 1831-1839.
Read now

Articles from other publishers (18)

Josephine A. Adattini, Annette S. Gross, Nicole Wong Doo & Andrew J. McLachlan. (2022) Real‐world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience. Pharmacology Research & Perspectives 10:5.
Crossref
Jonathan Webster & B. Douglas Smith. (2019) The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia. Clinical Therapeutics 41:2, pages 336-349.
Crossref
Alessandra Bettiol, Ettore Marconi, Niccolò Lombardi, Giada Crescioli, Filippo Gherlinzoni, Thomas Walley, Alfredo Vannacci, Alessandro Chinellato & Pietro Giusti. (2018) Pattern of Use and Long-Term Safety of Tyrosine Kinase Inhibitors: A Decade of Real-World Management of Chronic Myeloid Leukemia. Clinical Drug Investigation 38:9, pages 837-844.
Crossref
V.A. Shuvaev, Ol'ga Yur'evna Vinogradova, I.S. Martynkevich, N.V. Novitskaya, M.S. Fominykh, S.N. Tsareva, D.I. Shikhbabaeva, M.M. Pankrashkina, M.V. Chernikov, N.N. Sharkunov, I.I. Zotova, V.Yu. Udal'eva, E.V. Motyko & S.V. Voloshin. (2018) Clinical Experience and Perspectives of Bosutinib Use in Patients with Chronic Myeloid Leukemia. Clinical oncohematology 11:4, pages 288-294.
Crossref
Shovik Bandyopadhyay, Junjie Li, Elie Traer, Jeffrey W. Tyner, Amy Zhou, Stephen T. Oh & Ji-Xin Cheng. (2017) Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. PLOS ONE 12:7, pages e0179558.
Crossref
Jorge Luis Ángeles-Velázquez, Rafael Hurtado-Monroy, Pablo Vargas-Viveros, Silvia Carrillo-Muñoz & Myrna Candelaria-Hernández. (2016) Imatinib Intolerance Is Associated With Blastic Phase Development in Philadelphia Chromosome–Positive Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 16, pages S82-S85.
Crossref
Gabriel Etienne, Francoise Huguet, Agnès Guerci-Bresler, Franck E. Nicolini, Frédéric Maloisel, Valérie Coiteux, Charles Dauriac, Nathalie Carpentier, Isabelle Bourdeix, Michel Tulliez & Pascale Cony-Makhoul. (2016) Impact of ELN recommendations in the management of first-line treated chronic myeloid leukaemia patients: a French cross-sectional study. British Journal of Haematology 174:1, pages 71-80.
Crossref
Michael J. Mauro, Catherine Davis, Teresa Zyczynski & H. Jean Khoury. (2014) The role of observational studies in optimizing the clinical management of chronic myeloid leukemia. Therapeutic Advances in Hematology 6:1, pages 3-14.
Crossref
Yahiya Y. Syed, Paul L. McCormack & Greg L. Plosker. (2014) Bosutinib: A Review of Its Use in Patients with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia. BioDrugs 28:1, pages 107-120.
Crossref
Massimo Breccia & Giuliana Alimena. (2013) Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors. Leukemia Research 37:6, pages 713-720.
Crossref
Maren Rohrbacher & Joerg Hasford. 2013. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood 11 17 .
Atul SHARMA, Ankur BAHL, Vinod RAINA, Lalit KUMAR & Ritu GUPTA. (2012) Dasatinib in chronic myeloid leukemia: A limited Indian experience. Asia-Pacific Journal of Clinical Oncology 8:4, pages 375-379.
Crossref
Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri & Michele Baccarani. (2012) Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase. Critical Reviews in Oncology/Hematology 82:2, pages 159-170.
Crossref
P J Shami & M Deininger. (2011) Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR–ABL inhibitors as first-line therapy. Leukemia 26:2, pages 214-224.
Crossref
Paul L. McCormack & Susan J. Keam. (2011) Dasatinib. Drugs 71:13, pages 1771-1795.
Crossref
Carlos E. Vigil, Elizabeth A. Griffiths, Eunice S. Wang & Meir Wetzler. (2011) Interpretation of cytogenetic and molecular results in patients treated for CML. Blood Reviews 25:3, pages 139-146.
Crossref
Javier Pinilla-Ibarz, Jorge Cortes & Michael J. Mauro. (2011) Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer 117:4, pages 688-697.
Crossref
Jean-Baptiste Gaillard, Cécile Arnould, Sophie Bravo, Daniel Donadio, Carole Exbrayat, Eric Jourdan, Dorothée Reboul, Jean Chiesa & Thierry Lavabre-Bertrand. (2010) Exon 7 Deletion in the bcr-abl Gene Is Frequent in Chronic Myeloid Leukemia Patients and Is Not Correlated with Resistance against Imatinib . Molecular Cancer Therapeutics 9:11, pages 3083-3089.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.